TVR110

Asset

AAV9-delivered microRNA silences PMP22 to reduce protein overproduction and restore myelin structure and motor function.

Stage: Preclinical
Modality: Gene therapy
Target: PMP22; 1
Indication: 0
Trials: 1
Developer

Indications

1

Charcot-marie-tooth disease type 1A
Preclinical, armatusbio.com, 10 Oct 2026

In the full profile

Targets and what it contains1
Owner and partners1
Evidence for its targets1

Every asset’s record: target, stage, trials and the evidence behind it.